Εμφανίζονται 1 - 20 Αποτελέσματα από 103 για την αναζήτηση '"коронарное стентирование"', χρόνος αναζήτησης: 0,84δλ Περιορισμός αποτελεσμάτων
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
    Academic Journal

    Πηγή: Siberian Journal of Clinical and Experimental Medicine; Том 35, № 4 (2020); 103-110 ; Сибирский журнал клинической и экспериментальной медицины; Том 35, № 4 (2020); 103-110 ; 2713-265X ; 2713-2927

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.sibjcem.ru/jour/article/view/1080/583; Coorey G.M., Neubeck L., Mulley J., Redfern J. Effectiveness, acceptability and usefulness of mobile applications for cardiovascular disease self-management: Systematic review with meta-synthesis of quantitative and qualitative data. Eur. J. Prev. Cardiol. 2018;25(5):505–521. DOI:10.1177/2047487317750913.; Yusuf S., Joseph P., Rangarajan S., Islam S., Mente A., Hystad P. et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): А prospective cohort study. Lancet. 2020;395(10226):795–808. DOI:10.1016/S0140-6736(19)32008-2.; Tamburrano A., Vallone D., Carrozza C., Urbani A., Sanguinetti M., Nicolotti N. et al. Evaluation and cost estimation of laboratory test overuse in 43 commonly ordered parameters through a Computerized Clinical Decision Support System (CCDSS) in a large university hospital. PLoS One. 2020;15(8):e0237159. DOI:10.1371/journal.pone.0237159.; Kharbanda E.O., Asche S.E., Sinaiko A.R., Ekstrom H.L., Nordin J.D., Sherwood N.E. et al. Clinical Decision Support for Recognition and Management of Hypertension: A Randomized Trial. Pediatrics. 2018;141(2):e20172954. DOI:10.1542/peds.2017-2954.; Patterson B.W., Pulia M.S., Ravi S., Hoonakker P.L.T., Hundt A.S., Wiegmann D. et al. Scope and Influence of Electronic Health Record-Integrated Clinical Decision Support in the Emergency Department: A Systematic Review. Ann. Emerg. Med. 2019;74(2):285–296. DOI:10.1016/j.annemergmed.2018.10.034.; Трубачева И.А., Пушкарев Г.С., Акимова Е.В., Кузнецов В.А., Солдатова А.М., Акимов А.М. Патент РФ № 2649829 С1. Способ определения 10-летнего абсолютного суммарного риска смерти от сердечно-сосудистых заболеваний у мужчин трудоспособного возраста. Опубл. 04.04.2018.; Пушкарев Г.С., Кузнецов В.А., Акимова Е.В. Суммарный 10-летний риск смерти от сердечно-сосудистых заболеваний у мужчин 25–64 лет Тюмени. Профилактическая медицина. 2020;23(1):81–88. DOI:10.17116/profmed20202301177.; Assmann G., Cullen P., Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation. 2002;105(3):310–315. DOI:10.1161/hc0302.102575.; D’Agostino R.B. Sr., Pencina M.J., Massaro J.M., Coady S. Cardiovascular disease risk assessment: Insights from Framingham. Glob. Heart. 2013;8(1):11–23. DOI:10.1016/j.gheart.2013.01.001.; Neath A.A., Cavanaugh J.E. The Bayesian information criterion: background, derivation, and applications. WIREs Comp. Stat. 2012;4(2):199–203. DOI:10.1002/wics.199.; Hernández-Orallo J. ROC curves for regression. Pattern Recognition. 2013;46(12):3395–3411. DOI:10.1016/j.patcog.2013.06.014.; Warraich H.J., Califf R.M., Krumholz H.M. The digital transformation of medicine can revitalize the patient-clinician relationship. NPJ Digit. Med. 2018;1:49. DOI:10.1038/s41746-018-0060-2.; Wongvibulsin S., Martin S.S., Steinhubl S.R., Muse E.D. Connected health technology for cardiovascular disease prevention and management. Curr. Treat. Options Cardiovasc. Med. 2019;21(6):29. DOI:10.1007/s11936-019-0729-0.; Berger J.S., Jordan C.O., Lloyd-Jones D., Blumenthal R.S. Screening for cardiovascular risk in asymptomatic patients. J. Am. Coll. Cardiol. 2010;55(12):1169–1177. DOI:10.1016/j.jacc.2009.09.066.; Wannamethee S.G., Shaper A.G., Lennon L., Morris R.W. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch. Intern. Med. 2005;165(22):2644–2650. DOI:10.1001/archinte.165.22.2644.; Günaydın Z.Y., Karagöz A., Bektaş O., Kaya A., Kırış T., Erdoğan G. et al. Comparison of the Framingham risk and SCORE models in predicting the presence and severity of coronary artery disease considering SYNTAX score. Anatol. J. Cardiol. 2016;16(6):412–418. DOI:10.5152/AnatolJCardiol.2015.6317.; Versteylen M.O., Joosen I.A., Shaw L.J., Narula J., Hofstra L. Comparison of Framingham, PROCAM, SCORE, and Diamond Forrester to predict coronary atherosclerosis and cardiovascular events. J. Nucl. Cardiol. 2011;18(5):904–911. DOI:10.1007/s12350-011-9425-5.; D’Agostino R.B. Sr., Grundy S., Sullivan L.M., Wilson P.; CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286(2):180–187. DOI:10.1001/jama.286.2.180.; Brindle P., Beswick A., Fahey T., Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: A systematic review. Heart. 2006;92(12):1752–1759.; Cooper J.A., Miller G.J., Humphries S.E. A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study. Atherosclerosis. 2005;181(1):93–100. DOI:10.1016/j.atherosclerosis.2004.12.026.; Uthoff H., Staub D., Socrates T., Meyerhans A., Bundi B., Schmid H.P. et al. PROCAM-, FRAMINGHAM-, SCORE- and SMART-risk score for predicting cardiovascular morbidity and mortality in patients with overt atherosclerosis. Vasa. 2010;39(4):325–333. DOI:10.1024/0301-1526/a000057.; Woodward M., Brindle P., Tunstall-Pedoe H.; SIGN group on risk estimation. Adding social deprivation and family history to cardiovascular risk assessment: The ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart. 2007;93(2):172–176. DOI:10.1136/hrt.2006.108167.; Hippisley-Cox J., Coupland C., Vinogradova Y., Robson J., Brindle P. Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: A validation study. Heart. 2008;94(1):34–39. DOI:10.1136/hrt.2007.134890.; Трубачева И.А., Перминова О.А., Исаева Н.Н., Рудникович О.М. Патент РФ № 2 348 361 C1. Способ определения риска смерти от ишемической болезни сердца у мужчин, проживающих в условиях среднеурбанизированного города Западной Сибири. Опубл. 03.10.2009.; https://www.sibjcem.ru/jour/article/view/1080

  9. 9
  10. 10
  11. 11
    Academic Journal

    Πηγή: Патология кровообращения и кардиохирургия, Vol 17, Iss 1, Pp 91-95 (2015)

    Θεματικοί όροι: ИШЕМИЧЕСКАЯ БОЛЕЗНЬ СЕРДЦА, КОРОНАРНОЕ СТЕНТИРОВАНИЕ, РЕСТЕНОЗ, КОРОНАРНЫЙ СТЕНТ "CYPHER, КОРОНАРНЫЙ СТЕНТ "EUCATAX, Surgery, RD1-811

    Περιγραφή αρχείου: electronic resource

    Σύνδεσμος πρόσβασης: https://doaj.org/article/501b274cf42f4e2d9658268526e63e4d

  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
    Academic Journal

    Πηγή: Rational Pharmacotherapy in Cardiology; Vol 13, No 4 (2017); 532-540 ; Рациональная Фармакотерапия в Кардиологии; Vol 13, No 4 (2017); 532-540 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2017-13-4

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.rpcardio.com/jour/article/view/1515/1528; Pasceri V., Patti G., Nusca A., et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA study. Circulation. 2004;110:674-8.; Briguori С., Visconti G., Focaccio A., et al. Novel Approaches for Preventing or Limiting Events (Naples) II Trial: Impact of a Single High Loading Dose of Atorvastatin on Periprocedural Myocardial Infarction. JACC. 2009;54:2157-63.; Patti G., Pasceri V., Colonna G., et al. Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention. Results oftheARMYDA-ACS Randomized Trial. JACC. 2007;49:1272-8.; Sciascio G., Patti G., Pasceri V., et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE Randomized Trial. JACC. 2009;54:558-65.; Sardella G., Lucisano L., Mancone M., et al. Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial. Int J Cardiol. 2013;168:3715-20.; Winchester D.E., Wen X., Xie L., Bavry A.A. Evidence of Pre-Procedural Statin Therapy. A Meta-Analysis of Randomized Trials. JАСС. 2010;56:1099-109.; Lyu T., Zhao Y., Zhan T., et al. Effect of Statin Pretreatment on Myocardial Perfusion in Patients Undergoing Primary Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis. Clin Cardiol. 2013;69:E17-E24.; Jang Y., Zhu J., Ge J., et al. Preloading with atorvastatin before percutaneous coronary intervention in statin-naХve Asian patients with non-ST elevation acute coronary syndromes: A randomized study. J Cardiol. 2014;63:335-43.; Lyu T., Zhao Y., Zhang T., et al. Effect of Statin Pretreatment on Myocardial Perfusion in Patients Undergoing Primary Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis. Clin Cardiol. 2013;36:E17-E24.; Patti G., Ricottini E., Nusca A., et al. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN trial). Am J Cardiol. 2011;108:1-7.; Leoncini M., Toso A., Maioli M., et al. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). JACC. 2014;63:71-9.; Singh N, Lee J.,Huang J., et al. Benefit of statin pretreatmentin prevention of contrast-induced nephropathy in different adult patient population: systematic review and meta-analysis. Open Heart. 2014;1(1):e000127.; Roffi M., Patrono C., ColletJ.P., et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267-315.; Steg P.G., James S.K., Atar D., et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012;33:2569-619.; O'Gara P.T., Kushner F.G., Ascheim D.D., et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. JACC. 2013;61:485-510.; Amsterdam E.A., Wenger N.K., Brindis R.G., et al. 2014 AHA/ACC Guidelines for the Management of Patients With Non-ST-Elevation Acute Coronary Syndrome: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:e344-e426.; Windecker S., Kolh P., Alfonso F., et al. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541-619.; Levine G.N., Bates E.R., Blankenship J.C., et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Am Coll Cardiol. 2011;58(24):e44-122.; Catapano A.L., Graham I., De Backer G., et al. 2016 ESC/EAS Guidelines for the Managementof Dyslipidaemias. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;253:281-344.; Aronov D.M., Arabidze G.G., Akhmedzhanov N.M., et al. Diagnosis and correction of lipid metabolism disorders for the purpose of prevention and treatment of atherosclerosis. Russian recommendations, V revision. Rossiyskiy Kardiologicheskiy Zhurnal. 2012;96(4):2-32. (In Russ.) [Аронов Д.М., Арабидзе Г.Г., Ахмеджанов Н.М., и др.Диагностике и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, V пересмотр. Российский Кардиологический Журнал. 2012; 96(4):2-32].; https://www.rpcardio.com/jour/article/view/1515

  17. 17
    Academic Journal

    Πηγή: Medical Herald of the South of Russia; Том 8, № 4 (2017); 23-27 ; Медицинский вестник Юга России; Том 8, № 4 (2017); 23-27 ; 2618-7876 ; 2219-8075 ; 10.21886/2219-8075-2017-8-4

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.medicalherald.ru/jour/article/view/563/425; Акчурин Р.С., Власова Э.Е., Мершин К.В. Сахарный диабет и хирургическое лечение ишемической болезни сердца // Вестник РАМН. – 2012. – №1. – С.14-19.; Silva J.A., Escobar A., Collins T.J., Ramee S.R., White C.J. Unstable angina: a comparison of angioscopic fi ndings between diabetic and non-diabetic patients. // Circulation. – 1995. – V.92 (7). – P.1731–36.; Rask-Madsen C., King G.L. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. // Nat. Clin. Pract. Endocrinol. Metab. – 2007. – V.3(1). – P.46–56. doi:10.1038/ncpendmet0366; Сидоров Р.В., Петяев А.А., Петяев А.М., Поспелов Д.Ю., Долтмурзиева Н.С., Щетко В.Н. Временное внутрикоронарное шунтирование при реваскуляризации миокарда в условиях параллельного искусственного кровообращения // Медицинский вестник юга России. – 2016. – №1. – С.72-76.; BARI Investigators. Th e fi nal 10-year follow-up results from the BARI randomized trial. // J. Am. Coll. Cardiol. – 2007. – V.49(15). – P. 1600–6. doi:10.1016/j.jacc.2006.11.048; Kip K.E., Faxon D.P., Detre K.M., Yeh W., Kelsey S.F., Currier J.W. Coronary angioplasty in diabetic patients. Th e National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. // Circulation. – 1996. – V.94 (8). – P. 1818–25.; Brooks М.М., Jones R.Н, Bach R.G., Chaitman B.R., Kern M.J., Orszulak T.A. et al. Predictors of mortality and mortality from cardiac causes in the Bypass Angioplasty Revascularization Investigation (BARI) Randomized Trial and Registry // Circulation. – 2000. – Vоl.101, № 23. – Р. 2682–2689.; Feher М.D., Elkeles R.S. Lipid modifi cation and coronary heart disease in type 2 diabetes: diff erent the general population // Heart. – 1999. – Vol. 81. – P. 10–11.; King H., Aubert R.E., Herman W.H. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections // Diabetes Care. – 1998. – Vol. 21. – P. 1414–1431.; Weintraub W.S., Stein B., Kosinski А., Douglas J.S. Jr., Ghazzal Z.M., Jones E.L., et al. Outcome of coronary bypass surgery versus соronarу angioplasty in diabetic patients with multivessel coronary artery disease. // JACC. – 1998. – Vоl. 31. – Р. 10–19.; Timmis А.D. Diabetes. // Brit. Med. – 2001. – Vol. 59. – Р. 159–172.; Legrand V.M., Serruys P.W., Unger F., van Hout B.A., Vrolix M.C., Fransen G.M., et al. Th ree-year outcome aft er coronary stenting versus bypass surgery for the treatment of multivessel disease. // Ibid. – 2004. – Vol. 109(9). – P. 1114–1120. doi:10.1161/01.CIR.0000118504.61212.4B; Serruys P.W., Unger F., Sousa J.E., Jatene A., Bonnier H.J., Schönberger J.P., et al. Comparison of coronary artery bypass surgery and stenting for the treatment of multivessel disease. // N Engl J Med. – 2001. – V.344(15). – P.1117-24. doi:10.1056/NEJM200104123441502; Weintraub W.S., Grau-Sepulveda M.V., Weiss J.M., O’Brien S.M., Peterson E.D., Kolm P., et al. Comparative eff ectiveness of revascularization strategies. // N. Engl. J. Med. – 2012. – V.366 (16). – P.1467–76. doi:10.1056/NEJMoa1110717; Kappetein P., Head S.J., Morice M.C., Banning A.P., Serruys P.W., Mohr F.W., et al. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. // Eur. J. Cardiothorac. Surg. – 2013. – V.43 (5). – P. 1006–13. doi:10.1093/ejcts/ezt017; Banning A.P., Westaby S., Morice M.C., Kappetein A.P., Mohr F.W., Berti S., et al. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease comparison of outcomes with cardiac surgery and paclitaxeleluting stents. // J. Am. Coll. Cardiol. – 2010. – V.55(11). – P.1067–75. doi:10.1016/j.jacc.2009.09.057; Conroy R.M., Pyorala K., Fitzgerald A.P., Sans S., Menotti A., De Backer G., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. // Eur. Heart J. – 2003. – V.24. – P.987–1003.; Farkouh M.E., Domanski M., Sleeper L.A., Siami F.S., Dangas G., Mack M., et al. Strategies for multivessel revascularization in patients with diabetes. // N. Engl. J. Med. – 2012. – V.367(25). – P.2375–84. doi:10.1056/NEJMoa1211585; https://www.medicalherald.ru/jour/article/view/563

  18. 18
  19. 19
  20. 20